Immune-mediated inflammatory diseases differently affect IGRAs' accuracy for latent tuberculosis infection diagnosis in clinical practice

Irene Latorre1,2,3, Sonia Mínguez2,4, José-Manuel Carrascosa2,5, Juan Naves2,6, Raquel Villar-Hernández1,2,3, Beatrix Muriel1,2,3, Cristina Prat1,2,3, Esther García-García1,2,3, Irma Casas2,7, Eugeni Domènech2,6,8, Carlos Ferrándiz2,5, Lourdes Mateo2,4, Irma Domínguez1,2,3*

1 Servei de Microbiologia, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Badalona, Spain, 2 Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain, 3 CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Badalona, Spain, 4 Servei de Reumatologia, Hospital Universitari Germans Trias i Pujol, Institut d’Investigació Germans Trias i Pujol, Badalona, Spain, 5 Servei de Dermatologia, Hospital Universitari Germans Trias i Pujol, Institut d’Investigació Germans Trias i Pujol, Badalona, Spain, 6 Servei de Digestiu, Hospital Universitari Germans Trias i Pujol, Institut d’Investigació Germans Trias i Pujol, Badalona, Spain, 7 Servei de Medicina Preventiva, Hospital Universitari Germans Trias i Pujol, Institut d’Investigació Germans Trias i Pujol, Badalona, Spain, 8 CIBER Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Badalona, Spain

* jadominguez@igtp.cat

Abstract

Background
Clinical accuracy of IGRAs remains unclear on patients with immune-mediated inflammatory diseases (IMIDs). Here, we assess the impact of immunosuppressants and IMIDs on QuantiFERON-TB Gold In-Tube (QFN-G-IT) and T-SPOT.TB accuracy.

Methods
Patients with IMIDs who required latent tuberculosis infection (LTBI) screening were enrolled and classified into: (i) 50 patients with inflammatory rheumatic diseases, (ii) 50 patients with psoriasis and (iii) 30 patients with Crohn’s disease. A total of 44 healthy individuals without immunosuppression were also included as controls. Tuberculin skin test (TST), T-SPOT.TB and QFN-G-IT assays were performed. IGRAs were performed following manufacturer’s instructions.

Results
Immunosuppressant’s intake was more frequent on patients with Crohn’s disease and psoriasis. Positive IGRAs and TST results were reduced in Crohn’s disease patients, whereas rate of indeterminate T-SPOT.TB results was increased in this group with respect to the other IMIDs analysed and controls. When IFN-γ response was studied, the levels of this cytokine after mitogen stimulation were significantly lower in Crohn’s and inflammatory
rheumatic diseases than in psoriasis. Interestingly, psoriatic patients were the only ones not receiving corticosteroids. Furthermore, a negative correlation was observed between the IFN-γ secreted after mitogen stimulation and corticosteroids dose.

**Conclusions**

IMIDs seem to negatively affect the clinical accuracy of IGRAs, being Crohn’s disease patients the most affected individuals due to their concomitant drug-profile and impaired immune response.

**Introduction**

Patients with immune-mediated inflammatory diseases (IMIDs) have a higher risk of tuberculosis (TB) reactivation than common population because of the intake of different immunosuppressive therapies and/or their main disease itself. Tumour Necrosis Factor (TNF)-alpha (α) is a pro-inflammatory key cytokine playing an important role in the immune response against *Mycobacterium tuberculosis*. It is crucial for maintaining the granuloma formation and thus containing the infection caused by the bacilli. Therefore, ruling out latent tuberculosis infection (LTBI) and active TB is mandatory prior anti-TNF-α prescription as well as during treatment [1, 2].

Interferon (IFN)-gamma (γ) Release Assays (IGRAs) used for LTBI diagnosis detect the IFN-γ cytokine secreted by sensitized T-cells after stimulating with specific *M. tuberculosis* antigens [3]. There are two assay formats: QuantiFERON technology (QFN; Qiagen, Düsseldorf, Germany) and T-SPOT.TB (Oxford Immunotec, Abingdon, UK), both approved by the U.S. Food and Drug Administration (FDA) and the CE (for their use in Europe). Currently, these assays are useful tools for diagnosing LTBI because they are not affected by BCG-vaccination and/or non-tuberculous mycobacteria (NTM) sensitization [4–6]. In addition, IGRAs’ methodology contain a positive control [stimulation with phytohaemagglutinin (PHA) as a mitogen] which detects the presence of anergy. This control is very useful in individuals with a weak immune response due to the intake of several immunosuppressant therapies or the presence of a certain underlying disease. Therefore, the inclusion of this mitogen could be particularly useful in patients with IMIDs [7]. However, clinical performance of IGRAs remains still unclear in these kind of patients. Currently, available data on the usefulness of IGRAs in patients with IMIDs is diverse due to the population heterogeneity and the variety of immunosuppressant drug-regimens analysed [8, 9]. Therefore, research in this direction should be further considered. In the present study, we have investigated the impact of different immunosuppressant therapies and IMIDs on QFN-TB Gold In-Tube (QFN-G-IT) and T-SPOT.TB assays.

**Materials and methods**

**Study participants**

A total of 130 patients and 44 healthy controls were enrolled in the study. Samples were collected from Rheumatology, Dermatology, Gastroenterology and Preventive Medicine Departments located in Hospital Universitari Germans Trias I Pujol (Badalona, Spain). The study was approved by the Ethics Committee of the Hospital Germans Trias i Pujol. All experiments were performed in accordance with the relevant guidelines and regulations. All the patients...
enrolled in this study gave a written informed consent. A total of 11 mL of blood was collected from each patient.

**Tuberculin skin testing**

Tuberculin skin test (TST) was administered using the Mantoux method and interpreted according to Spanish Society of Pneumology Guidelines by qualified members of the research team. TST was considered positive when the induration was higher than 5mm [10]. In order to avoid TST booster effect over IGRAs, TST and blood extraction for T-SPOT.TB and QFN-G-IT were performed simultaneously [11]. The study was double-blinded: TST was interpreted without knowing IGRAs’ results, and at the same time, researchers did not know the clinical data and the TST result prior to performing the tests.

**IFN-γ release assays and results interpretation**

T-SPOT.TB and QFN-G-IT assays were performed and interpreted following manufacturer’s instructions. For T-SPOT.TB assay a total of 8 mL of blood were collected. Spot-forming cells (SFC) were counted using an automated AID ELISPOT reader (AID Systems, Strasberg, Germany). The results were also checked and validated by naked eye. The assay was considered positive when the test wells contained at least six SFC more than the negative control, and this number was at least twice the number of the negative control well. The result was considered indeterminate if both antigen-stimulated wells were negative and if the number of SFC in the positive control was less than 10; and/or if SFC counted in the negative control well was >10. For QFN-G-IT a total of 3 mL of blood was collected into three tubes (negative, TB-Antigen and positive). For this assay, a result was considered positive when the IU/mL of IFN-γ secreted was ≥0.35 for the TB-Antigen tube. A result was scored as indeterminate when the TB-antigen tube was negative and the mitogen tube presented less than 0.5 IU/mL of IFN-γ secreted (positive control); and/or if the negative control tube was higher than 8.0 IU/mL. Measurements >10IU/mL in QFN-G-IT were set as 10IU/mL according to the upper limit of the assay and manufacturer’s instructions.

**Statistical analysis**

Differences on the assay results based on the clinical therapeutic profile and the underlying disease was assessed and analysed using the Chi-square test. Association between the IFN-γ response and corticosteroid doses was assessed using Spearman correlation coefficient. The amount of IFN-γ secreted was investigated as well in each group. In this case, comparisons among the three study groups were performed using the Kruskall-Wallis test. In addition, Mann-Whitney U test was applied for pairwise comparisons. Differences were considered statistical significant when a p-value was <0.05. All analyses were performed using the SPSS statistical software for windows (SPSS version 15.0; SPSS Inc, Chicago, IL, USA). Graphical representation is based on GraphPad Prism version 4 (GraphPad Software, Inc, San Diego, CA).

**Results**

**Patient characteristics and concomitant drug-profile when IGRAs where performed**

We enrolled a total of 130 IMID patients who required LTBI screening before starting systemic immunosuppressive treatment or during its sustained use. Patients were screened in the course of their routine examinations and had no known risk of TB exposure. They were classified into three groups: (i) 50 patients with inflammatory rheumatic diseases, (ii) 50 patients with
moderate-to-severe psoriasis and (iii) 30 patients with Crohn’s disease. A total of 44 healthy individuals without immunosuppression were also included as controls. They were healthcare workers with no risk of TB exposure and recruited in the course of routine examinations.

Patient characteristics and their specific underlying disease regarding the study group is detailed in Table 1. Briefly, the proportion of patients on immunosuppressants (DMARDs or biologics) when IGRAs were performed varied significantly regarding the underlying disease \((p = 0.016)\). It was higher in patients with Crohn’s disease \((90\%; 27/30)\) and psoriasis \((82\%; 41/50)\) with respect to inflammatory rheumatic patients \((64\%; 32/50)\). The 75\% \((24/32)\) of rheumatic patients were receiving one DMARD and the 25\% \((8/32)\) were taking two. The 46.3\% \((19/41)\) of patients with psoriasis were receiving classic systemic treatment \((cyclosporine or methotrexate)\) and the 53.7\% \((22/41)\) were already taking biologicals \((infliximab, etanercept, adalimumab or ustekinumab)\). The 81.5\% \((22/27)\), 11.1\% \((3/27)\) and 7.4\% \((2/27)\) of Crohn’s disease patients were treated with azathioprine, methotrexate and biologicals \((infliximab)\) respectively. Corticosteroid therapy was frequent in patients with inflammatory rheumatic diseases \((40\%; 20/50)\) and Crohn’s disease \((33.3\%; 10/30)\), while it was absent in psoriatic patients \((Table 1)\).

IGRAs’ clinical accuracy regarding IMID type

Overall, the percentage of positive results by either of the two IGRAs were 22.7\% \((10/44)\), 22\% \((11/50)\), 24\% \((12/50)\), and 13.3\% \((4/30)\) in healthy controls, patients with psoriasis, rheumatic

---

**Table 1. Patients’ characteristics, final diagnosis and present treatment regarding IMID type.**

| VARIABLE                        | Psoriasis n = 50 (%) | Inflammatory rheumatic diseases n = 50 (%) | Crohn’s disease n = 30 (%) | Healthy controls n = 44 (%) |
|---------------------------------|----------------------|-------------------------------------------|-----------------------------|-----------------------------|
| Mean age (years) ± SD           | 45.52±13.05          | 49.58±13.11                                | 38.16±13.94                 | 36.21±7.22                 |
| Gender                          |                      |                                           |                             |                             |
| Male                            | 37 (74)              | 17 (34)                                   | 16 (53.3)                   | 10 (22.7)                   |
| Female                          | 13 (26)              | 33 (66)                                   | 14 (46.7)                   | 34 (77.3)                   |
| Diagnosis                       |                      |                                           |                             |                             |
| Moderate-to-severe psoriasis    | 50 (100)             | 0 (0)                                     | 0 (0)                       | N/A                         |
| Rheumatoid arthritis            | 0 (0)                | 16 (32)                                   | 0 (0)                       | N/A                         |
| Ankylosing spondylitis          | 0 (0)                | 12 (24)                                   | 0 (0)                       | N/A                         |
| Psoriatic arthritis             | 0 (0)                | 9 (18)                                    | 0 (0)                       | N/A                         |
| Crohn’s disease                 | 0 (0)                | 0 (0)                                     | 30 (100)                    | N/A                         |
| Other*                          | 0 (0)                | 13 (26)                                   | 0 (0)                       | N/A                         |
| Present corticoids              |                      |                                           |                             |                             |
| Yes                             | 0 (0)                | 20 (40)                                   | 10 (33.3)                   | N/A                         |
| No                              | 50 (100)             | 30 (60)                                   | 20 (66.7)                   | N/A                         |
| Present DMARDs                  |                      |                                           |                             |                             |
| Yes                             | 19 (38)              | 32 (64)                                   | 25 (83.3)                   | N/A                         |
| No                              | 31 (62)              | 18 (36)                                   | 5 (16.7)                    | N/A                         |
| Present biologics               |                      |                                           |                             |                             |
| Yes                             | 22 (44)              | 0 (0)                                     | 2 (6.7)                     | N/A                         |
| No                              | 28 (56)              | 50 (100)                                  | 28 (93.3)                   | N/A                         |

SD: standard deviation
*Systemic lupus erythematosus \((n = 4)\), SAPHO syndrome \((n = 4)\), seronegativepolyarthritis \((n = 3)\), undifferenciated spondilobarthropaty \((n = 1)\) and spondylitis associated with inflammatory bowel disease \((n = 1)\).
inflammatory diseases and Crohn’s disease respectively. In addition, a considerable percentage of IMIDs patients with negative TST (12.7%; 14/110) were positive for one of the two IGRAs. The percentage of positive results in patients with psoriasis, inflammatory arthritis, Crohn’s disease and healthy controls is represented for the three assays in Fig 1A–1C. The rate of positive results obtained by T-SPOT.TB, QFN-G-IT and TST was higher in patients with inflammatory rheumatic diseases, psoriasis and healthy controls with respect to Crohn’s disease individuals (differences not significant). Indeterminate results were obtained by T-SPOT.TB and QFN-G-IT in a 10% [13/130; 10 cases due to insufficient mitogen (PHA) response and 3 due to high response in negative control] and a 5.4% (7/130; all due to insufficient PHA response)] of the cases respectively. All indeterminate results due to insufficient PHA response corresponded with negative TSTs. The percentage of indeterminate results observed by T-SPOT.TB in patients with Crohn’s disease diagnosis was significantly higher than in rheumatic patients, those diagnosed with psoriasis and healthy controls (p = 0.003, p = 0.009 and p = 0.002 respectively). Seven out of the eight Crohn’s disease patients with indeterminate results corresponded to individuals receiving azathioprine. Furthermore, three of them were receiving corticosteroid therapy. Concordances between both IGRAs were good when they were analysed globally ($\kappa = 0.817$) and based on the study groups ($\kappa = 0.849$ for rheumatic inflammatory diseases, $\kappa = 0.799$ for psoriasis and $\kappa = 0.773$ for Crohn’s disease). By means of an univariate analysis, no significant differences were observed between the results obtained by either IGRAs or TST with biologics, corticoids or DMARDs received (Table 2).

Impact of immunosuppressive therapies on the IFN-γ response

The SFC and the IFN-γ response in T-SPOT.TB and QFN-G-IT was assessed in those positive responders after specific antigen stimulation, and evaluated regarding the underlying inflammatory disease. No significant differences were found between study groups (p = 0.101 and p = 0.574 respectively, data analysed with Kruskall-Wallis test). In order to further study the impact of different IMIDs on clinical assay accuracy, the amount of IFN-γ released after PHA stimulation was compared.
stimulation in QFN-G-IT was analysed in the overall population. Interestingly, in Crohn’s and rheumatic disease patients, the IFN-γ cytokine secreted by sensitized T cells after PHA stimulation was significantly lower with respect to psoriasis and healthy controls (Fig 2; p < 0.0001 for all comparisons). Psoriatic patients were the only ones not receiving corticosteroids. A correlation between the IFN-γ secreted after mitogen stimulation and dose (mg/day) of corticosteroid administered was performed. There was a negative moderate correlation (Fig 3; Spearman’s Rho = -0.489; p = 0.007).

Discussion

Investigations on IGRAs in high risk individuals are still limited, and it is necessary to compare and study how IMIDs with different immunosuppressive regimen can affect in vitro assays’ accuracy. Our research group have previously assessed in two independent studies the usefulness of IGRAs on patients with arthritic [12] and psoriatic [13] diseases, indicating that IGRAs seem to be helpful for LTBI diagnosis in such populations. In both studies we found that positive results for T-SPOT.TB/QFN-G-IT and the amount of T-cell response were not affected by clinical therapeutic profile. However, the effect of therapy on IFN-γ detection may depend on IMID type and its concomitant drug-treatment. The

Table 2. Association of the immunosuppressant treatment received with TST, QFN-G-IT and T-SPOT.TB positivity by means of univariate analysis.

| Risk Factors                                      | TST: n (%) |          |          | QFN-G-IT: n (%) |          |          | T-SPOT.TB: n (%) |          |
|--------------------------------------------------|------------|----------|----------|----------------|----------|----------|-----------------|----------|
|                                                  | Positive   | Negative | p-value  | Positive        | Negative | p-value  | Positive        | Negative | p-value  |
| Total                                            |            |          |          |                |          |          |                |          |          |
| Mean age (years) ± SD                            |            |          |          |                |          |          |                |          |          |
|                                                  | 52.53 ±12.50 | 44.42 ±14.47 | 0.031 | 57.19 ±10.68 | 43.62 ±13.81 | <0.0001 | 56.76 ±13.16 | 43.71 ±12.64 | <0.0001 |
| Gender                                           |            |          |          |                |          |          |                |          |          |
| Male                                             |            |          |          |                |          |          |                |          |          |
| Male                                             | 11 (64.7) | 56 (50.9) | 0.289 | 18 (81.8) | 51 (50.5) | 0.007 | 17 (77.3) | 46 (48.4) | 0.014  |
| Female                                           |            |          |          |                |          |          |                |          |          |
| Female                                           | 6 (35.3) | 54 (49.1) | 4 (18.2) | 50 (49.5) | 5 (22.7) | 49 (51.6) |
| Present immunosuppressants (DMARDs or biologics) |            |          |          |                |          |          |                |          |          |
| Yes                                              | 12 (70.6) | 85 (77.3) | 0.548c  | 17 (77.3) | 78 (77.2) | 0.966 | 15 (68.2) | 76 (80.0) | 0.259c  |
| No                                               | 5 (29.4) | 25 (22.7) | 5 (22.7) | 23 (22.8) | 7 (31.8) | 19 (20.0) |
| Present DMARDs                                   |            |          |          |                |          |          |                |          |          |
| Yes                                              | 9 (52.9) | 66 (60.0) | 0.582 | 11 (50.0) | 60 (59.4) | 0.418 | 11 (50.0) | 58 (61.1) | 0.342  |
| No                                               | 8 (47.1) | 44 (40.0) | 11 (50.0) | 41 (40.6) | 11 (50.0) | 37 (38.9) |
| Present biologics                                |            |          |          |                |          |          |                |          |          |
| Yes                                              | 3 (17.6) | 19 (17.3) | 1.000c  | 6 (27.3) | 18 (17.8) | 0.373c | 4 (18.2) | 18 (18.9) | 1.000c  |
| No                                               | 14 (82.4) | 91 (82.7) | 16 (72.7) | 83 (82.2) | 18 (81.8) | 77 (81.1) |
| Present corticoids                               |            |          |          |                |          |          |                |          |          |
| Yes                                              | 4 (23.5) | 26 (23.6) | 1.000c  | 5 (22.7) | 22 (21.8) | 0.923 | 5 (22.7) | 22 (23.2) | 0.966  |
| No                                               | 13 (76.5) | 84 (76.4) | 17 (77.3) | 79 (78.2) | 17 (77.3) | 73 (76.8) |

NA: non-applicable; SD: standard deviation. P values less than 0.05 were considered significant.

Excluding indeterminate QFN-G-IT and/or T-SPOT.TB results.

Significance on age was calculated using Student’s T test.

Significance was calculated using Fisher’s Exact test, since the 25% of expected frequency were less than 5.

https://doi.org/10.1371/journal.pone.0189202.t002
overall number of positive results obtained here by TST and IGRAs were reduced in patients suffering Crohn’s disease with respect to those with rheumatic disorders or psoriasis. Similarly, Ramos JM. et al. conducted a study using QFN-G-IT and TST assays in our region, observing that positive results were negatively affected by immunosuppressive therapy in patients with inflammatory bowel diseases. However indeterminate results obtained were low, therefore, no associations were established [14]. Low rates of positive IGRAs results on patients with inflammatory bowel diseases under azathioprine have been previously mentioned by others when they are compared with bowel disease patients under other drug-regimens or without immunosuppressive treatment [15]. Interestingly, the majority of Crohn’s disease patients included in our study were under this immunosuppressant drug.

Generally, the frequency of QFN-G-IT indeterminate results has been linked to patients with chronic inflammatory diseases under glucocorticoid use [8, 16–19]. In line with this, our results reveal that number of IGRA’s indeterminate results is even higher in Crohn’s disease patients under azathioprine. Moreover, the induced-mitogen response was reduced in this group and also in patients with rheumatic diseases with respect to those patients with psoriasis. Intriguingly, the 33.3% of Crohn’s disease patients and the 40% of individuals with rheumatic diseases were on corticosteroid therapy. Bélard E. et al. found a significant negative effect of prednisolone on IFN-γ response, indeterminate QFN-G-IT results and positive TST results. They also compared the IFN-γ response after mitogen stimulation in several therapy groups, and found that it was reduced in patients with corticosteroid treatment when they were compared with those not receiving treatment or other therapy without corticosteroid [16]. In order to study whether the immune response was influenced by corticosteroid treatment, we

Fig 2. IFN-γ released after mitogen (PHA) overnight stimulation (Mit-Nil) in QFN-G-IT based on the study group of patients analyzed. The median cytokine levels from each group is represented by a line. Mann-Whitney U analysis was applied for pairwise comparisons. Measurements >10IU/mL were set as 10IU/mL according to the upper limit of the assay and manufacturer’s instructions. Only significant differences were indicated in the figure. It was not possible to assess the IFN-γ response after PHA stimulation in T-SPOT.TB assay due to saturation in the control well (>250 spot-forming cells). Inflam. Arth: Inflammatory arthritis; PHA: Phytohaemagglutinin; QFN-G-IT: QuantiFERON-TB Gold In-Tube.

https://doi.org/10.1371/journal.pone.0189202.g002
correlated both IFN-γ released upon PHA stimulation with dose (mg/day) of corticosteroid administered, observing that this response diminished when the dose of corticosteroids augmented. In addition, a recent study has assessed the impact of corticosteroids on QFN-G-IT suggesting that they can significantly impair IGRAs accuracy [20]. Consequently, we have to pay attention when ruling out LTBI in this specific group of patients due to false-negative TST/IGRAs and low IFN-γ cytokine secretion that can lead to indeterminate results. In this direction, some studies report that a long in vitro stimulation of T cells (6–9 days) can detect a memory response and may be can be used to identify LTBI individuals who resulted to have negative IGRAs. More studies need to confirm these data, however, this could be a useful tool on patients under immunosuppressive treatment who have high risk of developing TB [21–23].

Taken together, here we describe how IMIDs can negatively affect the accuracy of IGRAs, being Crohn’s disease patients the most affected individuals due to their concomitant immunosuppressant drug-profile and impaired immune response. Therefore, in the absence of a gold standard, it seems prudent to diagnose LTBI using both the TST and IGRAs with the aim of detecting all possible cases in patients with IMIDs [24, 25], giving special attention to those with a poor accuracy of IGRAs and/or TST such as Crohn’s disease. In addition, the use of TST in psoriasis has to be taken with caution. Previous observations indicate that psoriasis can produce a TST hyper-reactivity due to a skin over-reaction to a broad range of antigens. Therefore, it is necessary to re-evaluate a positive TST reaction in these patients because in most situations it could lead to a LTBI over-diagnosis [26].
It is still necessary to make efforts for an accurate LTBI diagnosis in IMIDs’ patients. In this direction, a new improved IGRA version called QFN-Plus has appeared. This assay includes new designed peptides from *M. tuberculosis* capable to induce specific CD4 and CD8 T cells. Data about its better accuracy over classical IGRA is still limited, and there are not yet results evidencing a better sensitivity and specificity in this population [27–30]. Another encouraging approach seems to be the study of other cytokines different from IFN-γ. In the last years, the cytokine called IFN-γ-induced protein-10 (IP-10) has emerged as a promising biomarker for LTBI diagnosis that enables to rise sensitivity in conjunction with IFN-γ [31–34]. We should focus investigations on this direction: improving LTBI diagnostics on high-risk individuals, increasing sensitivity and minimizing false-negative and indeterminate results.

In conclusion, clinical accuracy of IGRA for LTBI diagnosis seems to be differentially affected by the IMID type. Particularly, Crohn’s disease and/or its concomitant immunosuppressive drug-profile could negatively affect accuracy of T-SPOT.TB and QFN-G-IT when compared with psoriasis or inflammatory rheumatic diseases. Therefore, it is important to be prudent when diagnosing LTBI in this kind of patients due to the high frequency of indeterminate results and an attenuated IFN-γ response.

**Author Contributions**

**Conceptualization:** Irene Latorre, José-Manuel Carrascosa, Cristina Prat, Carlos Ferrándiz, Lourdes Mateo, Jose Domínguez.

**Data curation:** Irene Latorre, Sonia Mínguez, Juan Naves.

**Formal analysis:** Irene Latorre, Raquel Villar-Hernández, Jose Domínguez.

**Funding acquisition:** José-Manuel Carrascosa, Eugeni Domènech, Carlos Ferrándiz, Lourdes Mateo, Jose Domínguez.

**Investigation:** Irene Latorre, Raquel Villar-Hernández, Beatriz Muriel, Esther García-García.

**Methodology:** Irene Latorre, Raquel Villar-Hernández, Jose Domínguez.

**Project administration:** José-Manuel Carrascosa, Eugeni Domènech, Carlos Ferrándiz, Lourdes Mateo, Jose Domínguez.

**Resources:** Sonia Mínguez, José-Manuel Carrascosa, Juan Naves, Cristina Prat, Irma Casas, Eugeni Domènech, Carlos Ferrándiz, Lourdes Mateo.

**Supervision:** Eugeni Domènech, Carlos Ferrándiz, Lourdes Mateo, Jose Domínguez.

**Validation:** Irene Latorre, Raquel Villar-Hernández.

**Visualization:** Irene Latorre, Raquel Villar-Hernández, Jose Domínguez.

**Writing – original draft:** Irene Latorre, Jose Domínguez.

**Writing – review & editing:** Irene Latorre, Sonia Mínguez, José-Manuel Carrascosa, Juan Naves, Raquel Villar-Hernández, Beatriz Muriel, Cristina Prat, Esther García-García, Irma Casas, Eugeni Domènech, Carlos Ferrándiz, Lourdes Mateo, Jose Domínguez.

**References**

1. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. *Arthritis Rheum.* 2005; 52(6):1766–72. https://doi.org/10.1002/art.21043 PMID: 15934089.
2. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014; 91:47–55. Ebup 2014/05/03. https://doi.org/10.3899/jrheum.140102 PMID: 24789000.

3. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet. 2000; 356(9235):1099–104. PMID: 11009160.

4. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J. 2011; 37(1):88–99. Ebup 2010/10/30. https://doi.org/10.1183/09031936.00115110 PMID: 21030451.

5. Dominguez J, Ruiz-Manzano J, De Souza-Galvao M, Latorre I, Mili C, Blanco S, et al. Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis. Clin Vaccine Immunol. 2008; 15(1):168–71. Ebup 2007/11/06. https://doi.org/10.1128/CVI.00364-07 PMID: 17978008.

6. Ferrara G, Losi M, D’Amico R, Roovers P, Piro R, Meacci M, et al. Use in routine clinical practice of two commercially blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006; 367(9519):1328–34. https://doi.org/10.1016/S0140-6736(06)68579-6 PMID: 16631911.

7. Dominguez J, Latorre I. Role of the T-cell interferon-gamma release assays in preventing reactivation of latent tuberculosis infection in immunosuppressed patients in treatment with anti-TNF agents. J Crohns Collitis. 2008; 2(3):250–4. https://doi.org/10.1016/j.jcrohns.2008.05.007 PMID: 21172220.

8. Redelman-Sidi G, Sepkowitz KA. INF-gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med. 2013; 188(4):422–31. Ebup 2012/12/25. https://doi.org/10.1164/rcrm.2012-1621CJ PMID: 23262514.

9. Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, et al. Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. Am J Respir Crit Care Med. 2014; 190(10):1668–76. https://doi.org/10.1164/rcrm.201405-0967OC PMID: 25303140.

10. Ruiz-Manzano J, Blanquer R, Caipe JL, Caminero JA, Cayla J, Dominguez JA, et al. Diagnosis and treatment of tuberculosis. Arch Bronconeumol. 2008; 44(10):551–66. PMID: 19006636.

11. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-gamma test results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One. 2009; 4(12):e8517. https://doi.org/10.1371/journal.pone.0008517 PMID: 20041113.

12. Minguze S, Latorre I, Mateo L, Lacoma I, Díaz J, Oliveira A, et al. Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment. Clin Rheumatol. 2012; 31(5):785–94. https://doi.org/10.1007/s10067-012-1938-z PMID: 22271230.

13. Latorre I, Carrascosa JM, Vilavella M, Díaz J, Prat C, Domínguez J, et al. Diagnosis of tuberculosis infection by interferon-gamma release assays in patients with psoriasis. J Infect. 2014; 69(6):600–6. Ebup 2014/08/26. https://doi.org/10.1016/j.jinf.2014.07.026 PMID: 25148944.

14. Ramos JM, Masia M, Rodriguez JC, Lopez C, Padilla S, Robledano C, et al. Negative effect of immune-suppressive therapy in the performance of the QuantiFERON gold in-tube test in patients with immune-mediated inflammatory diseases. Clin Exp Med. 2013; 13(3):177–86. https://doi.org/10.1007/s10238-012-0192-7 PMID: 22736247.

15. Wong SH, Ip M, Tang W, Lin Z, Kee C, Hung E, et al. Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients. Inflamm Bowel Dis. 2014; 20(11):2067–72. https://doi.org/10.1097/MIB.0000000000000147 PMID: 25189454.

16. Beirard E, Semb S, Ruhwald M, Werleinrd AM, Soborg B, Jensen FK, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. 2011; 17(11):2340–9. https://doi.org/10.1002/ibd.21605 PMID: 21319275.

17. Calabrese C, Overman RA, Dusetzina SB, Hajj-All RA. Evaluating indeterminate interferon-gamma release assay results in patients with chronic inflammatory diseases receiving immunosuppressive therapy. Arthritis Care Res (Hoboken). 2015; 67(8):1063–9. https://doi.org/10.1002acr.22454 PMID: 25186123.

18. Helwig U, Muller M, Hedderich J, Schreiber S. Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients. J Crohns Colitis. 2012; 6(4):419–24. https://doi.org/10.1016j.crohns.2011.09.011 PMID: 23980867.

19. Bao L, Li T, Diao N, Shen Y, Zhao L, Zhang Y, et al. Fluctuating Behavior and Influential Factors in the Performance of the QuantiFERON-TB Gold In-Tube Assay in the Diagnosis of Tuberculosis. PloS one. 2015; 10(8):e0103763. https://doi.org/10.1371/journal.pone.0103763 PMID: 26287382.
20. Edwards A, Gao Y, Allan RN, Ball D, de Graaf H, Coelho T, et al. Corticosteroids and infliximab impair the performance of interferon-gamma release assays used for diagnosis of latent tuberculosis. Thorax. 2017. doi:10.1136/thoraxjnl-2016-209397 PMID: 28159773.

21. Leyten EM, Arend SM, Prins C, Cobelens FG, Ottenhoff TH, van Dissel JT. Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol. 2007; 14(7):880–5. doi:10.1128/CVI.00132-07 PMID: 17507543.

22. Butera O, Chiacchio T, Carrara S, Casetti R, Vanini V, Meraviglia S, et al. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infect Dis. 2009; 9:182. doi:10.1186/1471-2334-9-182 PMID: 19930588.

23. Casas I, Latorre I, Esteve M, Ruiz-Manzano J, Rodriguez D, Prat C, et al. Evaluation of interferon-gamma release assays in the diagnosis of recent tuberculosis infection in healthcare workers. PLoS One. 2009; 4(8):e6686. Epub 2009/08/25. doi:10.1371/journal.pone.0006686 PMID: 19701460.

24. Kim HC, Jo KW, Jung YJ, Yoo B, Lee CK, Kim YG, et al. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay. Scand J Infect Dis. 2014; 46(11):763–9. doi:10.3109/00365548.2014.938691 PMID: 25195652.

25. Santin M, Garcia-Garcia JM, Rigau D, Allet N, Anibarro L, Casas I, et al. Executive summary of the guidelines for the use of interferon-gamma release assays in the diagnosis of tuberculosis infection. Enferm Infecc Microbiol Clin. 2016; 34(5):304–8. doi:10.1016/j.eimc.2015.11.021 PMID: 26926262.

26. Bassukas ID, Kosmidou M, Gaitanis G, Tsiouri G, Tsianos E. Patients with psoriasis are more likely to be treated for latent tuberculosis infection prior to biologics than patients with inflammatory bowel disease. Acta dermato-venereologica. 2011; 91(4):444–6. doi:10.2340/00015555-1106 PMID: 21547342.

27. Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF, et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur Respir J. 2016. doi:10.1183/13993003.00510-2016 PMID: 27390280.

28. Yi L, Sasaki Y, Nagai H, Ishikawa S, Takamori M, Sakashita K, et al. Evaluation of QuantiFERON-TB Gold Plus for detection of Mycobacterium tuberculosis infection in Japan. Sci Rep. 2016; 6:30617. doi:10.1038/srep30617 PMID: 27470684.

29. Hoffmann H, Avsar K, Gores R, Mavi SC, Hofmann-Thiel S. Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT. Clin Microbiol Infect. 2016. doi:10.1016/j.cmi.2016.05.006 PMID: 27184875.

30. Petruccioli E, Chiacchio T, Pepioni I, Vanini V, Urso R, Cuzzi G, et al. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. J Infect. 2016; 73(6):588–97. doi:10.1016/j.jinf.2016.09.008 PMID: 27717779.

31. Latorre I, Diaz J, Mialdea I, Serra-Vidal M, Allet N, Prat C, et al. IP-10 is an accurate biomarker for the diagnosis of tuberculosis in children. J Infect. 2014; 69(6):590–9. Epub 2014/07/01. doi:10.1016/j.jinf.2014.06.013 PMID: 24975172.

32. Chegou NN, Heyckendorf J, Walzl G, Lange C, Ruhwald M. Beyond the IFN-gamma horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. Eur Respir J. 2014; 43(5):1472–86. Epub 2013/12/07. doi:10.1183/09031936.00151413 PMID: 24317770.

33. Guo SJ, Jia LQ, Hu QJ, Long HY, Pang CS, Wen FQ. Diagnostic accuracy of interferon gamma-induced protein 10 for tuberculosis: a meta-analysis. Int J Clin Exp Med. 2014; 7(1):93–100. PMID: 24482693.

34. Villar-Hernandez R, Latorre I, Miguez S, Diaz J, Garcia-Garcia E, Muriel-Moreno B, et al. Use of IFN-gamma and IP-10 detection in the diagnosis of latent tuberculosis infection in patients with inflammatory rheumatic diseases. J Infect. 2017; 75(4):315–25. doi:10.1016/j.jinf.2017.07.004 PMID: 28751171.